pre-IPO PHARMA

COMPANY OVERVIEW

Thetis Pharmaceuticals is a biopharmaceutical company developing immuno-resolving oral therapies for the treatment of IBD. The Thetis approach is based on leveraging the robust pharmacology of bioactive lipids with its proprietary technology platform to overcome the stability, manufacturing, formulation and patentability hurdles that have limited their development as pharmaceutical agents.


LOCATION

  • Branford, CT, USA

  • THERAPEUTIC AREAS

  • Gastrointestinal Disease
  • Inflammatory Disease
  • Liver Disease

  • WEBSITE

    https://thetispharma.com/cms2/


    CAREER WEBSITE

    None


    SOCIAL MEDIA


    INVESTORS

    connecticut-innovations stonehenge-growth-capital


    PRESS RELEASES


    May 23, 2018

    Thetis Pharmaceuticals Receives $1.9 Million Fast-Track NIH Grant to Advance Novel Inflammatory Bowel Disease Drug Pipeline Toward Clinical Investigation


    May 7, 2018

    FDA and Industry Veteran Brian E. Harvey, MD, PhD, Joins Thetis Pharmaceuticals as Senior Medical Director


    Nov 16, 2017

    Thetis Pharmaceuticals Awarded $2.3 Million Fast-Track NIH Grant to Develop Immuno-Resolving Therapy for Inflammatory Bowel Disease


    Nov 16, 2017

    Thetis Pharmaceuticals Awarded $2.3 Million Fast-Track NIH Grant to Develop Immuno-Resolving Therapy for Inflammatory Bowel Disease


    Apr 14, 2016

    Thetis Pharmaceuticals to Present at the World Orphan Drug Congress on TP-252, an Investigational Drug for Familial Adenomatous Polyposis


    For More Press Releases


    Google Analytics Alternative